Advertisement

International Urology and Nephrology

, Volume 50, Issue 12, pp 2201–2206 | Cite as

Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis

  • Dengpiao Xie
  • Jianting Wang
  • Xinping Wu
  • Mingquan LiEmail author
Nephrology - Review
  • 268 Downloads

Abstract

Background

The efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemic patients with chronic kidney disease.

Methods

We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemic patients with CKD.

Results

Four studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96–1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45–0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07–13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD − 76.1 μg/L; 95% CI − 91.8 to − 60.3, p < 0.00001) and ferritin (WMD − 63.6 μg/L; 95% CI − 96.6 to − 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups.

Conclusion

Daprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemic patients with chronic kidney disease in the future.

Keywords

Meta-analysis Daprodustat Chronic kidney disease 

Notes

Acknowledgements

Thanks Yuhua He, Guoshuan Zhu, and Lijie Li for useful suggestions.

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Research involving human and animal participants

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included the study.

References

  1. 1.
    Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67(6):2089–2100CrossRefGoogle Scholar
  2. 2.
    Yano Y, Fujimoto S, Asahi K et al (2012) Prevalence of chronic kidney disease in China. Lancet 379(9818):815CrossRefGoogle Scholar
  3. 3.
    Hsu CY (2002) Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 11(3):337CrossRefGoogle Scholar
  4. 4.
    Levin A, Rocco M (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis 50(3):471–530CrossRefGoogle Scholar
  5. 5.
    Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23(10):1631–1634CrossRefGoogle Scholar
  6. 6.
    Bonomini M, Del Vecchio L, Sirolli V et al (2016) New treatment approaches for the anemia of CKD. Am J Kidney Dis 67(1):133–142CrossRefGoogle Scholar
  7. 7.
    Möcks J (2000) Cardiovascular mortality in haemodialysis patients treated with epoetin beta—a retrospective study. Nephron 86(4):455–462CrossRefGoogle Scholar
  8. 8.
    Weiner DE, Tighiouart H, Vlagopoulos PT et al (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16(6):1803CrossRefGoogle Scholar
  9. 9.
    Zehnder C, Zuber M, Sulzer M et al (1992) Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 61(1):21CrossRefGoogle Scholar
  10. 10.
    Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584CrossRefGoogle Scholar
  11. 11.
    Iseki K, Kohagura K (2007) Anemia as a risk factor for chronic kidney disease. Kidney Int 72(107):S4–S9CrossRefGoogle Scholar
  12. 12.
    Horwich TB, Fonarow GC, Hamilton MA et al (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 8(4):235–236Google Scholar
  13. 13.
    Schmid H, Jelkmann W (2016) Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs 25(8):901–916CrossRefGoogle Scholar
  14. 14.
    Beuck S, Schänzer W, Thevis M (2012) Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 4(11):830–845CrossRefGoogle Scholar
  15. 15.
    Hara K, Takahashi N, Wakamatsu A et al (2015) Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet 30(6):410–418CrossRefGoogle Scholar
  16. 16.
    Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815–826CrossRefGoogle Scholar
  17. 17.
    Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie 5(2):S38Google Scholar
  18. 18.
    Holdstock L, Meadowcroft AM, Maier R et al (2016) Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27(4):1234CrossRefGoogle Scholar
  19. 19.
    Brigandi RA, Johnson B, Oei C et al (2016) A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis 67(6):861–871CrossRefGoogle Scholar
  20. 20.
    Akizawa T, Tsubakihara Y, Nangaku M et al (2016) Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol 45(2):127CrossRefGoogle Scholar
  21. 21.
    Mann JF (1999) What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 14(Suppl 2):29CrossRefGoogle Scholar
  22. 22.
    Mcclellan WM, Flanders WD, Langston RD et al (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13(7):1928CrossRefGoogle Scholar
  23. 23.
    Locatelli F, Nissenson AR, Barrett BJ et al (2008) Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 74(10):1237CrossRefGoogle Scholar
  24. 24.
    National Kidney Foundation (2006) Correction of anemia with Epoetin Alfa in chronic kidney disease. NEJM N Engl J Med 355(20):2085–2098CrossRefGoogle Scholar
  25. 25.
    Kulaksiz H, Gehrke SG, Janetzko A et al (2004) Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 53(5):735–743CrossRefGoogle Scholar
  26. 26.
    Nicolas G, Bennoun M, Devaux I et al (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98(15):8780CrossRefGoogle Scholar
  27. 27.
    Nicolas G, Chauvet C, Viatte L et al (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Investig 110(7):1037CrossRefGoogle Scholar
  28. 28.
    Babitt JL, Lin HY (2010) Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 55(4):726CrossRefGoogle Scholar
  29. 29.
    Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30(1):15–30CrossRefGoogle Scholar
  30. 30.
    Atkinson MA, Kim JY, Roy CN et al (2015) Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol 30(4):635–643CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Dengpiao Xie
    • 1
  • Jianting Wang
    • 2
  • Xinping Wu
    • 1
  • Mingquan Li
    • 3
    Email author
  1. 1.Chengdu University of Traditional Chinese MedicineChengduChina
  2. 2.People’s Hospital of Fujian ProvinceFuzhouChina
  3. 3.The Teaching Hospital of Chengdu University of Traditional Chinese MedicineChengduChina

Personalised recommendations